Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 24c
Tweet
Share
E-mailGet Alerts LRMR Hot Sheet
Join SI Premium – FREE
Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q4 EPS of ($0.73), $0.24 worse than the analyst estimate of ($0.49).
For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
- Lument Finance Trust (LFT) Misses Q2 EPS by 17c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
